During the past decade, Policlinico G. B. Rossi conducted 18 clinical trials. In the 10-year time frame, 18 clinical trials started and 8 clinical trials were completed, i.e. on average, 44.4% percent of trials that started reached the finish line to date. In the past 5 years, 3 clinical trials started and 4 clinical trials were completed. i.e. 133.3% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Policlinico G. B. Rossi" #1 sponsor was "Gruppo Italiano Malattie EMatologiche dell'Adulto" with 11 trials, followed by "Azienda Ospedaliera Universitaria Integrata Verona" with 4 trials sponsored, "Fondazione Italiana Linfomi ONLUS" with 4 trials sponsored, "Gruppo Italiano Trapianto di Midollo Osseo" with 4 trials sponsored and "Abbott" with 4 trials sponsored. Other sponsors include 17 different institutions and companies that sponsored additional 22 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Policlinico G. B. Rossi" #1 collaborator was "Azienda Policlinico Umberto I" with 2 trials as a collaborator, "Consorzio Mario Negri Sud" with 1 trials as a collaborator, "GITIL (GRUPPO ITALIANO TERAPIE INNOVATIVE NEI LINFOMI)" with 1 trials as a collaborator, "Gruppo Italiano Malattie EMatologiche dell'Adulto" with 1 trials as a collaborator and "IRCCS Azienda Ospedaliero-Universitaria di Bologna" with 1 trials as a collaborator. Other collaborators include -1 different institutions and companies that were collaborators in the rest 9 trials.

According to Clinical.Site data, the most researched conditions in "Policlinico G. B. Rossi" are "Leukemia" (3 trials), "Carcinoma, Non-Small-Cell Lung" (2 trials), "Chronic Myeloid Leukemia" (2 trials), "Hematologic Diseases" (2 trials) and "Pancreatic Fistula" (2 trials). Many other conditions were trialed in "Policlinico G. B. Rossi" in a lesser frequency.

Most popular intervention types in "Policlinico G. B. Rossi" are "Drug" (33 trials), "Other" (7 trials), "Procedure" (3 trials), "Device" (2 trials) and "Dietary Supplement" (1 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (4 trials), "Atrasentan" (2 trials), "Imatinib" (2 trials), "Macitentan" (2 trials) and "Nilotinib" (2 trials). Other intervention names were less common.

The vast majority of trials in "Policlinico G. B. Rossi" are 43 trials for "All" genders, 2 trials for "Female" genders and 2 trials for "Male" genders.

Currently, there are NaN active trials in "Policlinico G. B. Rossi". undefined are not yet recruiting, 1 are recruiting, 5 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 33 completed trials in Policlinico G. B. Rossi, undefined suspended trials, and 1 terminated clinical trials to date.

Out of the total trials that were conducted in Policlinico G. B. Rossi, 0 "Phase 1" clinical trials were conducted, 13 "Phase 2" clinical trials and 20 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 5 trials that are defined as “Not Applicable".